Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Next Previous
Trial Profile

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ 90301900 (Primary) ; Carboplatin; Durvalumab; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CONVERGE
  • Sponsors Johnson & Johnson Innovation

Most Recent Events

  • 21 Jan 2025 According to NANOBIOTIX Media Release, the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial.
  • 11 Dec 2024 Planned initiation date (estimated date of first participant enrollment) changed from 31 Oct 2024 to 20 Dec 2024.
  • 11 Dec 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top